GALAPAGOS NV

Galapagos NV American Depositary Receipt represents shares in Galapagos NV, a fully integrated biotechnology company headquartered in Mechelen, Belgium, and founded in 1999. The company focuses on transforming patient outcomes through life-changing science and innovation in immunology and oncology. It develops best-in-class therapies using multiple drug modalities, including small molecules, biologicals, and advanced cell therapies such as CAR-T products manufactured via a decentralized, point-of-care platform for rapid vein-to-vein delivery. Key therapeutic areas encompass immunology indications like rheumatoid arthritis, ulcerative colitis, axial spondyloarthritis, dermatomyositis, and systemic lupus erythematosus, alongside oncology programs targeting non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and multiple myeloma. Galapagos synergizes internal expertise with external partnerships to accelerate discovery, development, and delivery of innovative medicines addressing high unmet medical needs. With operations spanning Europe and the United States, it maintains a deep pipeline and collaborates with leading organizations to pioneer next-generation treatments for serious diseases.